Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
NCT06843408Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of axatilimab in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Incyte. Primary endpoints: Number of participants with Treatment-emergent Adverse Events and Objective Response in the First 6 Cycles. Started Jun 2025; status: active, not recruiting.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06843408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843408.